Nephrotoxicity of nonsteroidal anti-inflammatory drugs: Physiologic foundations and clinical implications

American Journal of Medicine

Volumn 106, Issue 5 B, 1999, Pages 13S-24S

  Whelton, Andrew ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; SULINDAC; TIAPROFENIC ACID;

ANALGESIC NEPHROPATHY; CLINICAL TRIAL; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DRUG ANTAGONISM; EDEMA; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY PAPILLA NECROSIS; META ANALYSIS; NEPHROTIC SYNDROME; NEPHROTOXICITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; SODIUM RETENTION;

EID: 0033620643     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(99)00113-8     Document Type: Conference Paper

References (83)

1. Whelton A, Watson J. Nonsteroidal anti-inflammatory drugs: effects on kidney function. In: De Broe ME, Porter GA, Bennett WM, Verpooten GA, eds. Clinical Nephrotoxins: Renal Injury From Drugs and Chemicals. Dordrecht, Netherlands: Kluwer Academic Publishers, 1997:209-222.
2. Whelton A., Hamilton C.W. Nonsteroidal antiinflammatory drugs effects on kidney function . J Clin Pharmacol. 31:1991;588-598.
3. Whelton A., Stout R.L., Spilman P.S., Klasson D.L. Renal effects of ibuprofen, piroxicam, and sulindac in patients with asymptomatic renal failure a prospective, randomized, crossover comparison . Ann Intern Med. 112:1990;568-576.
4. Bush T.M., Shlotzhauer T.L., Imai K. Nonsteroidal antiinflammatory drugs proposed guidelines for monitoring toxicity . West J Med. 155:1991;39-42.
5. 2 formation. N Engl J Med. 1988;319:689-698, 761-767.
6. 2 on chloride transport across the rabbit thick ascending limb of Henle selective inhibition of the medullary portion . J Clin Invest. 64:1979;495-502.
7. 2 across the isolated perfused rabbit collecting tubule. J Clin Invest. 59:1977;1099-1104.
8. 1) on the permeability response of the toad bladder to vasopressin, theophylline, and adenosine 3′,5′-monophosphate. Nature. 205:1985;397-398.
9. Anderson R.J., Berl T., McDonald K.M., Schrier R.W. Evidence for an in vivo antagonism between vasopressin and prostaglandin in the mammalian kidney. J Clin Invest. 56:1975;420-426.
10. Aronoff G.R. Therapeutic implications associated with renal studies of nabumetone. J Rheumatol. 19:(suppl 36):1992;25-31.
11. Murray M.D., Brater D.C. Nonsteroidal antiinflammatory drugs. Clin Geriatr Med. 6:1990;365-397.
12. Schooley R.T., Wagley P.F., Lietman P.S. Edema associated with ibuprofen therapy. JAMA. 237:1977;1716-1717.
13. Blum M., Aviram A. Ibuprofen-induced hyponatremia. Rheumatol Rehab. 19:1980;258-259.
14. Clive D.M., Stroff J.S. Renal syndromes associated with nonsteroidal anti-inflammatory drugs. N Engl J Med. 310:1984;563-572.
15. Whelton A. Nonsteroidal anti-inflammatory drugs: effects on kidney function. In: Greenberg A, ed. Primer on Kidney Diseases. San Diego, CA: Academic Press, 1994:163-167.
16. Akbarpour F., Afrasiabi A., Vazirin N.D. Severe hyperkalemia caused by indomethacin and potassium supplementation. South Med J. 78:1985;756-757.
17. Mor R., Pitlik S., Rosenfeld J.B. Indomethacin- and Moduretic-induced hyperkalemia. Isr J Med Sci. 19:1983;535-537.
18. Galler M., Folkert V.W., Schlondorff D. Reversible acute renal insufficiency and hyperkalemia following indomethacin therapy. JAMA. 246:1981;154-155.
19. Nicholls M.G., Espiner E.A. Indomethacin-induced azotemia and hyperkalemia a case study . N Z Med J. 94:1981;377-379.
20. Findling J.W., Beckstrom D., Rawsthorne L., et al. Indomethacin-induced hyperkalemia in 3 patients with gouty arthritis. JAMA. 244:1980;1127-1128.
21. Paladini G., Tonazzi C. Indomethacin-induced hyperkalemia and renal failure in multiple myeloma. Acta Haematol (Basel). 68:1982;256-260.
22. Tan S.Y., Shapiro R., Franco R., et al. Indomethacin-induced prostaglandin inhibition with hyperkalemia. Ann Intern Med. 90:1979;783-785.
23. Walshe J.J., Venuto R.C. Acute oliguric renal failure induced by indomethacin possible mechanisms . Ann Intern Med. 91:1979;47-49.
24. Arisz L., Donker A.J.M., Brentjens J.R.H., van der Hem G.K. The effect of indomethacin on proteinuria and kidney function in the nephrotic syndrome. Acta Med Scand. 199:1976;121-125.
25. Kleinknecht C., Broyer M., Gubler M.-C., Palcoux J.-H. Irreversible renal failure after indomethacin in steroid-resistant nephrosis. N Engl J Med. 302:1980;691.
26. Blackshear H., Napier J.S., Davidman M., Stillman M.T. Renal complications of nonsteroidal anti-inflammatory drugs identification and monitoring of those at risk . Semin Arthritis Rheum. 14:1985;163-175.
27. Favre L., Glasson P., Vallotton M.B. Reversible acute renal failure from combined triamterene and indomethacin a study in healthy subjects . Ann Intern Med. 96:1982;317-320.
28. McCarthy J.T., Torres V.E., Romero J.C., et al. Acute intrinsic renal failure induced by indomethacin role of prostaglandin synthesis inhibition . Mayo Clin Proc. 57:1982;289-296.
29. Whelton A., Stout R.L., Spilman P.S., Klassen D.K. Renal effects of ibuprofen, piroxicam, and sulindac in patients with asymptomatic renal failure a prospective, randomized, crossover comparison . Ann Intern Med. 112:1990;568-576.
30. Brater D.C., Anderson S., Baird B., Campbell W.B. Effects of ibuprofen, naproxen, and sulindac on prostaglandins in men. Kidney Int. 27:1985;66-73.
31. Sedor J.R., Williams S.L., Chremos A.N., et al. Effects of sulindac and indomethacin on renal prostaglandin synthesis. Clin Pharmacol Ther. 36:1984;85-91.
32. Ciabattoni G., Cinotti G.A., Pierucci A., et al. Effects of sulindac and ibuprofen in patients with chronic glomerular disease evidence for the dependence of renal function on prostacyclin . N Engl J Med. 310:1984;279-283.
33. Bunning R.D., Barth W.F. Sulindac a potentially renal sparing nonsteroidal anti-inflammatory drug . JAMA. 248:1982;2864-2867.
34. Quintero E., Gines P., Arroyo V., et al. Sulindac reduces the urinary excretion of prostaglandins and impairs renal function in patients with cirrhosis and ascites. Nephron. 42:1986;298-303.
35. Abraham P.A., Keane W.F. Glomerular and interstitial disease induced by nonsteroidal anti-inflammatory drugs. Am J Nephrol. 4:1984;1-6.
36. Levin M.L. Patterns of tubulo-interstitial damage associated with nonsteroidal anti-inflammatory drugs. Semin Nephrol. 8:1988;55-61.
37. Bender W.L., Whelton A., Beschorner W.E., et al. Interstitial nephritis, proteinuria, and renal failure caused by nonsteroidal anti-inflammatory drugs immunologic characteristics of the inflammatory infiltrate . Am J Med. 76:1984;1006-1012.
38. Stachura L., Jayakumar S., Bourke E. T and B lymphocyte subsets in fenoprofen nephropathy. Am J Med. 75:1983;9-16.
39. Radford M.G., Holley K.E., Grande J.P., et al. Reversible membranous nephropathy associated with the use of nonsteroidal anti-inflammatory drugs. JAMA. 276:1996;466-469.
40. Husserl F.E., Lange R.K., Kantrow C.M. Jr. Renal papillary necrosis and pyelonephritis accompanying fenoprofen therapy. JAMA. 242:1979;1896-1898.
41. Robertson C.E., Ford M.J., Van Someren V., et al. Mefenamic acid nephropathy. Lancet. 2:1980;232-233.
42. Shah G.M., Muhalwas K.K., Winer R.L. Renal papillary necrosis due to ibuprofen. Arthritis Rheum. 24:1981;1208-1210.
43. Morales A., Steyn J. Papillary necrosis following phenylbutazone ingestion. Arch Surg. 103:1971;420-421.
44. Stein J.H., Fadem S.Z. The renal circulation. JAMA. 239:1978;1308-1312.
45. Kirschenbaum M.A., White N., Stein J.H., Ferris T.F. Redistribution of renal cortical blood flow during inhibition of prostaglandin synthesis. Am J Med. 227:1974;801-805.
46. Gregg N.J., Elseviers M.M., DeBroe M.E., Bach P.H. Epidemiology and mechanistic basis of analgesic-associated nephropathy. Toxicol Lett. 46:1989;141-151.
47. Kincaid-Smith P. Effects of non-narcotic analgesics on the kidney. Drugs. 32:(suppl 4):1986;108-128.
48. Lauler D.P., Schreiner G.E., David A. Renal medullary necrosis. Am J Med. 29:1960;132.
49. Sargent J.C., Sargent J.W. Unilateral renal papillary necrosis. J Urol. 73:1955;757.
50. Atta M.G., Whelton A. Acute renal papillary necrosis induced by ibuprofen. Am J Therapeut. 4:1997;55-60.
51. Bergnes M.A. Recovery of papillae in renal papillary necrosis report of two cases . Arch Pathol. 75:1963;501.
52. Lindholm T. On renal papillary necrosis with special reference to the diagnostic importance of papillary fragments in the urine, therapy, and prognosis. Acta Med Scand. 167:1960;319.
53. Lindvall N. Radiological changes of renal papillary necrosis. Kidney Int. 13:1978;93.
54. Lindvall N. Renal papillary necrosis a roentgenographic study of 155 cases . Acta Radiol (Stockholm). 192:(suppl 1):1960;1.
55. Buckalew VM Jr. Analgesic abuse nephropathy. In: Greenberg A, ed. Primer on Kidney Disease. San Diego, CA: Academic Press, 1994:192-196.
56. Hultengren N., Lagergren C., Ljungquist A. Carcinoma of the renal pelvis in renal papillary necrosis. Acta Chir Scand. 130:1965;314-320.
57. Bengtsson U., Johansen S., Angervall L. Malignancies of the urinary tract and their relation to analgesic abuse. Kidney Int. 13:1978;107-113.
58. McCredie M., Ford J.M., Stuart Taylor J., Stewart J.H. Analgesics and cancer of the pelvis in New South Wales. Cancer. 49:1982;2617-2625.
59. Bach P.H., Berndt W.O., Delzell E., et al. A safety assessment of fixed combinations of acetaminophen and acetylsalicylic acid, coformulated with caffeine. Renal Failure. 20:1998;749-762.
60. Collins R., Pete R., MacMahon S., et al. Blood pressure, stroke, and coronary heart disease: part 2. Short-term reductions in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 335:1990;827-838.
61. Ruoff GE. The impact of nonsteroidal anti-inflammatory drugs on hypertension: alternative analgesics for patients at risk. Clin Ther. 1998;20:376-387.
62. Curb J.D., Borhani N.O., Schnaper R., et al. Detection and treatment of hypertension in elderly individuals. Am J Epidemiol. 121:1985;371-376.
63. Johnson A.G., Simons L.A., Simons J., et al. Non-steroidal anti-inflammatory drugs and hypertension in the elderly a community-based cross-sectional study . Br J Clin Pharmacol. 35:1993;455-459.
64. Houston M.C. Nonsteroidal anti-inflammatory drugs and antihypertensives. Am J Med. 90:(suppl 5A):1991;42-47.
65. Pope J.E., Anderson J.J., Felson D.T. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med. 153:1993;477-484.
66. Johnson A.G., Nguyen T.V., Day R.O. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med. 21:1994;289-300.
67. Brater D.C. Diuretic therapy. N Engl J Med. 339:1998;387-395.
68. Chennavasin P., Seiwell R., Brater D.C. Pharmacokinetic and -dynamic analysis of the indomethacin-furosemide interaction in man. J Pharmacol Exp Ther. 215:1980;77-81.
69. Kaojarern S., Chennavasin P., Anderson S., Brater D.C. Nephron site of effect of nonsteroidal anti-inflammatory drugs on solute excretion in humans. Am J Physiol. 244:(suppl):1983;F134-F139.
70. Johnson A.G. NSAIDs and increased blood pressure what is the clinical significance? Drug Safety. 17:1997;277-289.
71. Sahoul M.Z., al-Kiek R., Ivanovich P., Mujais S.K. Nonsteroidal anti-inflammatory drugs and antihypertensives cooperative malfeasance . Nephron. 56:1990;345-352.
72. Murthy V.S., Waldron T.L., Goldberg M.E. The mechanism of bradykinin potentiation after inhibition of angiotensin-converting enzyme by SQ 14,225 in conscious rabbits. Circ Res. 43:(suppl 1):1978;40-45.
73. 2 receptors, prostaglandins, kinins, and nitric oxide . J Hypertens. 13:1995;1779-1784.
74. Dyer R.D., Huttner J.J., Tan S.Y., Muldrow P.J. Prostaglandin synthesis by vascular smooth muscle cells is stimulated by bradykinin, prazosin, and hydralazine. Prog Lipid Res. 20:1981;557-560.
75. Gurwitz J.H., Avorn J., Bohn R.L., et al. Initiation of antihypertensive treatment during nonsteroidal anti-inflammatory drug therapy. JAMA. 272:1994;781-786.
76. Heerdink E.R., Leufkens H.G., Herings R.M.C., et al. NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. Arch Intern Med. 158:1998;1108-1112.
77. Harris R.C., McKanna J.A., Akai Y., et al. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest. 94:1994;2504-2510.
78. Cowley B.D. Jr, Mussel M.J., Douglas D., Wilkins W. In vivo and in vitro osmotic regulation of HSP-70 and prostaglandin synthase gene expression in kidney cells. Am J Physiol. 269:1995;F854-F862.
79. Morham S.G., Langenback R., Loftin C.D. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell. 83:1995;473-482.
80. Khan K.N., Venturini C.M., Bunch R.T., et al. Interspecies differences in renal localization of cyclooxygenase isoforms implications in nonsteroidal antiinflammatory drug-related nephrotoxicity . Toxicol Pathol. 26:1998;612-620.
81. Gresham AK, Venturini CM, Edwards D, Ornberg RL. COX-2 expression is induced in the macula densa in volume depleted dogs. FASEB J. 1997;11:A-461.
82. Tomasoni S., Noris M., Zapella S., Remuzzi G. Upregulation of renal and systemic cyclooxygenase 2 in patients with active lupus nephritis. J Am Soc Nephrol. 9:1998;1202-1212.
83. Kömhoff M., Gröne H.-J., Klein T., Seyberth H.W., Nüsing R.M. Localization of cyclooxygenase-1 and 2 in adult and fetal human kidney implication for renal function . Am J Physiol. 272:1997;F460-F468.